Hydrochlorothiazide: A Comprehensive Guide for API Importers, Manufacturers, and Compounding Pharmacies
Hydrochlorothiazide (HCTZ) is a cornerstone thiazide diuretic, prescribed globally for hypertension, edema, and chronic kidney disease.
As a pharmaceutical API supplier, we address the critical needs of API importers, medicine manufacturers, and compounding pharmacies with high-purity, GMP-compliant Hydrochlorothiazide API.
This guide explores its applications, sourcing strategies, and future trends—equipping you to optimize formulations, reduce costs, and ensure regulatory compliance.
What is Hydrochlorothiazide?
Hydrochlorothiazide API, chemically designated as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide (CAS 58-93-5), is a white crystalline powder classified as a thiazide diuretic Active Pharmaceutical Ingredient (API).
It features slight water solubility but dissolves readily in sodium hydroxide solutions.
This molecule remains the cornerstone of antihypertensive and edema management therapies globally, with over 100 million prescriptions annually in the US alone.
Its stability, well-understood pharmacokinetics, and compatibility with combination therapies make it indispensable for the manufacturing of cardiovascular drugs.
It is a sulfonamide diuretic that inhibits sodium reabsorption in the kidneys, promoting fluid and electrolyte excretion. Unlike loop diuretics (e.g., furosemide), it acts on the distal convoluted tubule, making it an ideal choice for mild-to-moderate fluid retention.
Is Hydrochlorothiazide a Diuretic?
Yes, Hydrochlorothiazide is a first-line thiazide diuretic API.
It inhibits sodium and chloride reabsorption in the distal convoluted tubules of the kidneys, promoting osmotic water excretion.
Unlike loop diuretics, HCTZ exhibits moderate efficacy with a longer duration (6–12 hours), making it ideal for sustained blood pressure control rather than acute fluid overload.
Its diuretic action precedes its antihypertensive effects, which manifest even after electrolyte balance normalizes—a critical consideration for formulation stability and dosing regimens.
Clinical Relevance:
Hypertension: First-line therapy for mild hypertension (12.5–25 mg/day).
Edema: Manages fluid retention in conditions such as heart failure, cirrhosis, and renal disorders.
Does Hydrochlorothiazide Cause Weight Gain?
No—weight gain is not a typical adverse effect.
Contrarily, initial HCTZ therapy may cause transient weight loss (1-2 kg) due to fluid excretion.
However, long-term use may cause weight gain due to:
Electrolyte imbalances (e.g., hypokalemia) disrupt metabolism.
Increased appetite from fluid rebound post-diuresis.
Manufacturers must note that electrolyte imbalances (e.g., hypokalemia, hyponatremia) from prolonged use can indirectly trigger metabolic alterations.
Compounding pharmacists should monitor excipient choices in formulations to mitigate risks—e.g., potassium-sparing combinations or electrolyte-replenishing additives in custom dosages.
Mitigation Strategies:
Monitor electrolytes (potassium, sodium) monthly.
Combine with potassium-sparing diuretics (e.g., amiloride).
What Are Brand Names of Hydrochlorothiazide?
HCTZ is commercialized under more than 30 brand names globally, both as monotherapies and fixed-dose combinations (FDCs).
Its key brands include:
| Brand Name | Combination | Manufacturer |
|---|---|---|
| Modazar® | Losartan + HCTZ | Gardenia Pharmacies |
| Hydrodiuril® | HCTZ monotherapy | Merck & Co. |
| Enalapril-HCTZ | Enalapril + HCTZ | Minclinic EU |
| Zestoretic® | Lisinopril + HCTZ | AstraZeneca |
FDCs account for more than 60% of HCTZ formulations, emphasizing API demand for combination products.
What Is Hydrochlorothiazide Used For?
Core Therapeutic Applications
Hypertension: First-line monotherapy or FDC with ACE inhibitors/beta-blockers.
Edema: Associated with heart failure, renal dysfunction, or cirrhosis.
Nephrolithiasis: Off-label use for calcium-containing kidney stones.
Emerging Applications
Recent studies indicate HCTZ’s potential in:
Fibrosis Reduction: Via TGF-β/Smad pathway inhibition.
Cardioprotection: Mitigating left ventricular hypertrophy in chronic hypertension.
Manufacturers should explore patent opportunities in these niches.
How Hydrochlorothiazide Works (Mechanism of Action)
HCTZ’s pharmacological action involves:
Na+/Cl- Cotransport Inhibition: Blocks NCC channels in renal distal tubules → reduces plasma volume.
Vasodilation: Opens calcium-activated potassium (KCA) channels in vascular smooth muscle.
Long-Term BP Control: Suppresses renin-angiotensin-aldosterone system (RAAS) via sodium depletion.
Binding to Human Serum Albumin (HSA):
Spectroscopic studies confirm HCTZ binds to HSA’s Sudlow Site II (subdomain IIIA), inducing conformational changes that prolong systemic circulation.
This interaction necessitates albumin compatibility testing during the development of injectable formulations.
Clinical Implications:
Onset: 2 hours; peak effect at 4–6 hours.
Half-Life: 5–15 hours (prolonged in renal impairment).
Hydrochlorothiazide Dosage and Administration
Standard Dosages
Monotherapy: 12.5–50 mg/day (tablets/capsules).
Combination Therapies: 12.5–25 mg with ACE inhibitors/ARBs.
Critical Administration Guidelines
Bioavailability: Peak plasma concentration in 2–4 hours; administer fasting for optimal absorption.
Renal Impairment: Avoid if CrCl <30 mL/min (risk of azotemia).
Sodium Depletion: Correct volume deficits pre-administration to prevent hypotension
How Long Does Agomelatine Take to Work?
Timeline of Effects:
Week 1: Improved sleep architecture (↓ latency, ↑ SWS).
Week 2–4: Reduction in depressive symptoms (50% responder rate).
Week 6–8: Full therapeutic effect; sustained for 6+ months with adherence.
Strategies for Non-Responders:
Dose escalation to 50 mg.
Augmentation with aripiprazole (10–15 mg) for treatment-resistant depression.
Administration Tips:
Please take it in the morning to avoid nocturia.
Adjust dose for renal impairment (CrCl <30 mL/min: avoid)
Hydrochlorothiazide Precautions and Drug Interactions
High-Risk Interactions
| Interacting Drug | Risk | Management |
|---|---|---|
| Lithium | ↑ Lithium toxicity | Monitor serum levels |
| Digoxin | ↑ Arrhythmia risk (hypokalemia) | Potassium-sparing combinations |
| NSAIDs | ↓ HCTZ efficacy | Avoid concurrent use |
Patient Safety Protocols
Contraindications: Sulfonamide allergy, anuria, severe hepatic impairment.
Monitoring: Serum electrolytes (baseline + quarterly), renal function, and uric acid.
What Are the Long-Term Side Effects of Hydrochlorothiazide?
Chronic HCTZ use requires vigilance for:
Electrolyte Depletion: Hypokalemia (in 15% of patients), hyponatremia, and hypomagnesemia.
Metabolic Shifts: Hyperglycemia, hypercalcemia, hyperuricemia (↑ gout risk).
Renal Toxicity: Reduced glomerular filtration in pre-existing CKD.
Mitigation Strategies:
Formulation Solutions: Enteric-coated K+ supplements in FDC tablets.
Dosing Adjustments: Limit to 12.5 mg/day in elderly patients.
Monitoring Recommendations:
Serum K⁺, Na⁺, and uric acid every 3–6 months.
Renal function tests (creatinine, eGFR)
Hydrochlorothiazide vs. Other Medications
Drug Name | Advantages | Limitations |
|---|---|---|
Furosemide | Rapid-onset for acute edema | Weak antihypertensive effect |
Potassium-sparing | Risk of hyperkalemia | |
Chlorthalidone | Longer half-life | Higher hypokalemia risk |
Cost Comparison (Per 100 Tabs):
HCTZ: 30 USD (generic)
Chlorthalidone: 60 USD
Additionally, HCTZ is a preferred choice in hypertension protocols due to its lower cost and compatibility with FDCs.
Is Hydrochlorothiazide Safe During Pregnancy?
Category B (1st trimester); Category D (2nd/3rd trimesters):
1st Trimester: Limited fetal risk in animal studies, but human data show possible CV malformations (1.2% incidence).
2nd/3rd Trimesters: May cause fetal electrolyte imbalances, jaundice, or placental hypoperfusion.
Manufacturing Note:
Labeling must include: “Contraindicated in pregnancy except for life-threatening edema. Use during lactation may suppress milk production.”
How Long Does Hydrochlorothiazide Take to Work?
Diuretic Effect: Onset at 2 hours; peaks at 4 hours.
Antihypertensive Action: Significant BP reduction after 3–4 weeks.
Implications for Clinical Trials:
Bioequivalence Studies: Sample at T_max=4 hours.
Patient Adherence Packaging: Use calendar blisters for 28-day cycles.
Global Sourcing Tips for Hydrochlorothiazide API
Supplier Vetting:
Ensure compliance with USP, EP, and JP.
Audit facilities for GMP, ISO 13485.
Bulk Purchasing:
Negotiate discounts for 100kg+ orders.
Opt for FOB or CIF terms to manage logistics effectively.
Quality Assurance:
Demand COA with HPLC purity ≥99.0%.
Request stability testing (accelerated conditions)
Compounding Pharmacy Guidelines for Hydrochlorothiazide Formulations
Best Practices
Excipient Compatibility: Avoid lactose in patients with sodium depletion (use pH-neutral binders such as MCC and starch). Lubricants: Magnesium stearate (≤1% to avoid bioavailability issues).
Dosage Forms: Capsules (>90% stability at 25°C/60% RH), suspensions (14-day expiry).
Custom FDCs: Test HCTZ-ramipril blends for polymorphic transitions via XRD.
Packaging:
Light-resistant amber vials for stability.
Include moisture indicators (e.g., silica gel packets)
Stability Protocols
Storage: 15–30°C in airtight, light-resistant containers.
Beyond-Use Dating: 6 months for solid dosages
Conclusion: Strategic Partnerships for Hypertension Drug Supply Chains
Hydrochlorothiazide remains the cornerstone API for $18B+ antihypertensive markets.
With global regulatory tailwinds—Nigeria’s tax exemptions, India’s PLI incentives, and WHO prequalification pathways—API importers and manufacturers can achieve:
15–20% cost reduction via bulk sourcing and duty optimization.
Zero port rejection through GMP documentation (DMF, CEP).
First-mover advantage in emerging anti-fibrosis applications.
Ready to streamline your HCTZ supply chain?
Disclaimer:
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
